Researchers at the Francis Crick Institute and AlveoliX have developed the first human lung-on-chip model using stem cells ...

Dear Dr. Roach: In a recent column, you noted that many patients do not properly use their inhaled asthma/chronic obstructive pulmonary disease (COPD) medications, but you didn't tell us how to ...

In a recent column, you noted that many patients do not properly use their inhaled asthma/chronic obstructive pulmonary ...

Tezepelumab may allow patients with severe, uncontrolled asthma who are oral corticosteroid-dependent to decrease their OCS use.

The researchers concluded from their analysis that “exhaled propanoic and nonanoic acids may serve as complementary non-invasive biomarkers for monitoring controlled asthma, independently of tobacco ...

Background: Long-acting beta-agonist (LABA) plus long-acting muscarinic antagonist (LAMA) is superior to monotherapy or corticosteroid/LABA in terms of improving lung function, alleviating symptoms ...

AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had ...

AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (UTHR) announced today that it will host a webcast to review data from the successful TETON-2 ...

The FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, drugmaker Verona Pharma announced on Wednesday. A first-in-class ...